This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bosslet, K. Articles by Hoffmann, D. Search for Related Content PubMed PubMed Citation Articles by Bosslet, K. Articles by Hoffmann, D.

Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis

Research Laboratories of Behringwerke AG, P. O. Box 11 40, D-35001 Marburg, Germany

A two component system, consisting of a fusion protein and an appropriate prodrug, suited to perform selective tumor therapy in vivo is presented. The fusion protein, due to its humanized carcinoembryonic antigen-specific variable region, specifically binds to carcinoembryonic antigen-expressing tumors and has an enzymatic activity comparable to that of human ß-glucuronidase. The prodrug is a nontoxic glucuronide-spacer derivative of doxorubicin decomposing to doxorubicin by enzymatic deglucuronidation.

In vivo studies in nude mice bearing human carcinoembryonic antigen-expressing tumor xenografts revealed that 7 days after injection of 20 mg/kg fusion protein a high specificity ratio (>100:1) was obtained between tumor and plasma or tumor and normal tissues. Injection of 250 mg/kg of prodrug at day 7 resulted in tumor therapeutic effects superior to those of conventional chemotherapy without any detectable toxicity. These superior therapeutic effects which were observed using established human tumor xenografts can be explained by the approximately 4–12-fold higher doxorubicin concentrations found in tumors of mice treated with fusion protein and prodrug than in those treated with the maximal tolerable dose of drug alone.

The nondetectable toxicity in the animals treated with fusion protein and prodrug is probably caused by up to 5-fold lower drug concentrations in normal tissues compared to the animals treated with doxorubicin. Thus, a more tumor-selective therapy, resulting in stronger therapeutic effects and reduced toxicity seems to be possible by the appropriate use of the humanized nontoxic fusion protein and the nontoxic prodrug.

¹ To whom requests for reprints should be addressed.

Received 11/16/93. Accepted 2/17/94.

This article has been cited by other articles:

				S. K. Sharma, R. B. Pedley, J. Bhatia, G. M. Boxer, E. El-Emir, U. Qureshi, B. Tolner, H. Lowe, N. P. Michael, N. Minton, et al. Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy Clin. Cancer Res., January 15, 2005; 11(2): 814 - 825. [Abstract] [Full Text] [PDF]

				M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]

				M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen Enzyme-Catalyzed Activation of Anticancer Prodrugs Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102. [Abstract] [Full Text] [PDF]

				T. E. Murdter, G. Friedel, J. T. Backman, M. McClellan, M. Schick, M. Gerken, K. Bosslet, P. Fritz, H. Toomes, H. K. Kroemer, et al. Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by beta -Glucuronidase J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 223 - 228. [Abstract] [Full Text] [PDF]

				B. Sperker, C. Tomkiewicz, O. Burk, R. Barouki, and H. K. Kroemer Regulation of Human {beta}-Glucuronidase by A23187 and Thapsigargin in the Hepatoma Cell Line HepG2 Mol. Pharmacol., February 1, 2001; 59(2): 177 - 182. [Abstract] [Full Text]

				H. J. Haisma, M. F. Sernee, E. Hooijberg, R. H. Brakenhoff, I. H. v.d. Meulen-Muileman, H. M. Pinedo, and E. Boven Construction and Characterization of a Fusion Protein of Single-Chain Anti-CD20 Antibody and Human beta -Glucuronidase for Antibody-Directed Enzyme Prodrug Therapy Blood, July 1, 1998; 92(1): 184 - 190. [Abstract] [Full Text] [PDF]

				G. K. Smith, S. Banks, T. A. Blumenkopf, M. Cory, J. Humphreys, R. M. Laethem, J. Miller, C. P. Moxham, R. Mullin, P. H. Ray, et al. Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in Vivo Stable Prodrugs of Methotrexate J. Biol. Chem., June 20, 1997; 272(25): 15804 - 15816. [Abstract] [Full Text] [PDF]

				B. Sperker, T. E. Mürdter, M. Schick, K. Eckhardt, K. Bosslet, and H. K. Kroemer Interindividual Variability in Expression and Activity of Human beta -Glucuronidase in Liver and Kidney: Consequences for Drug Metabolism J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 914 - 920. [Abstract] [Full Text]